

LumiRISK™

A multi-cancer panel provides a comprehensive coverage of 45 genes related to 11 cancers to assess an individual's risk of developing hereditary cancer. Knowing their risk of cancer early can enable patients to take better preventive action.

Cancer types covered:

**Breast Ovarian Endometrial Pancreas Colorectal Prostate
Lung Gastric Kidney Thyroid Melanoma**

Recommended for: Individuals who wish to be informed of their cancer risk especially those who have a family history of cancer.

Genes Evaluated

APC	BRCA2*	EGFR <i>T790M</i>	MEN1	NF1	SDHA	TSC1
ATM	BRIP1	EPCAM^	MET	PALB2	SDHB	TSC2
AXIN2	CDH1	ERCC2	MLH1*	PMS2	SDHC	VHL
BAP1	CDK4 <i>R24C & R24H</i>	FANCA	MSH2*	PTEN	SDHD	
BARD1	CDKN2A	FH	MSH6	RAD51C	SMAD4	
BMPR1A	CHEK2	FLCN	MUTYH	RAD51D	STK11	
BRCA1*	DICER1	HOXB13 <i>G84E</i>	NBN	RET	TP53	

LumiTHERA™

Analyzes 17 genes, including those in the Homologous Recombination Repair (HRR) pathway. The panel covers guideline-recommended genes to match actionable results with U.S. FDA-approved targeted therapies.

Cancer types covered:

**Breast Ovarian Endometrial Pancreas Colorectal
Prostate**

Recommended for: Patients who have breast, ovarian, prostate, pancreatic or colorectal cancer that may be inherited.

Genes Evaluated

ATM	BRCA2*	EPCAM^	MSH6	PMS2	RAD51D
BARD1	BRIP1	MLH1*	MUTYH	PTEN	TP53
BRCA1*	CHEK2	MSH2*	PALB2	RAD51C	

LumiFOCUS™

Cancer-specific panels examine genes associated with specific hereditary cancers.

Recommended for

Individuals who wish to be informed of their cancer risk especially those who have relatives diagnosed with the same type of cancer at a younger age.

LumiFOCUS™ Gynaecological

ATM	BRCA2*	CDH1	EPCAM^	MSH2*	NBN	PALB2	PTEN	RAD51D	TP53
BRCA1*	BRIP1	CHEK2	MLH1*	MSH6	NF1	PMS2	RAD51C	STK11	

LumiFOCUS™ Breast

ATM	BRCA2*	EPCAM^	NF1	RAD51C	TP53
BARD1	CDH1	MLH1^	PALB2	RAD51D	
BRCA1*	CHEK2	MSH2^	PTEN	STK11	

LumiFOCUS™ Colon

APC	BRCA1^	MLH1*	MUTYH	SMAD4
AXIN2	BRCA2^	MSH2*	PMS2	STK11
BMPR1A	EPCAM^	MSH6	PTEN	

LumiFOCUS™ Gastric

BMPR1A	CDH1	MSH2*	PMS2
BRCA1^	EPCAM^	MSH6	SMAD4
BRCA2^	MLH1*	MUTYH	STK11

LumiFOCUS™ Kidney

BAP1	EPCAM^	MET	PTEN	SDHC	TSC2
BRCA1^	FH	MLH1^	SDHA	SDHD	VHL
BRCA2^	FLCN	MSH2^	SDHB	TSC1	

LumiFOCUS™ Pancreas

ATM	CDKN2A	MSH2*	PMS2
BRCA1*	EPCAM^	MSH6	STK11
BRCA2*	MLH1*	PALB2	TP53

LumiFOCUS™ Prostate

ATM	CHEK2	HOXB13 G84E	MSH6	RAD51D
BRCA1*	EPCAM^	MLH1*	PALB2	
BRCA2*	FANCA	MSH2*	PMS2	

Technical Specifications of Lumi Series Tests

Lucence's upgraded amplicon-based enrichment chemistry now features mirror barcoding, a dual-strand independent labeling technique for genomic DNA next generation sequencing (NGS). Our sequence analysis covers the entire coding sequences†# of listed genes in the panel and includes CNV for Large Genomic Rearrangements detection in **BRCA1**, **BRCA2**, **EPCAM**, **MLH1**, and **MSH2**.

† **CDK4**, **EGFR**, **HOXB13**, **MET** and **RET**: Sequencing analysis only for important hotspots in these genes

EPCAM: Sequencing analysis is not available for this gene.

Sensitivity > 99%

Sample Requirement

2 Streck tubes of blood (18ml in total)

OR

2 EDTA tubes of blood (18ml in total)

Turnaround Time

15 Working Days

*Includes sequencing and CNV analyses

^Includes CNV analysis only

Customer support: +65 6592 5102 sales.asean@lucence.com

lucence.com

Lucence Service Laboratory 211 Henderson Road #04-02, Henderson Industrial Park, Singapore 159552
Lucence Diagnostics Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (Licence Number: 1710039/03/202) under the Healthcare Services Act 2020. GST Registered 201605840N. Refer to www.lucence.com/order-terms for Terms of Use. © 2022 Lucence Diagnostics Pte. Ltd. All Rights Reserved.

Information for non-US medical professionals only

M2006E-SG-04. August 2024